These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 9044824

  • 1. Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice.
    Jankun J, Keck RW, Skrzypczak-Jankun E, Swiercz R.
    Cancer Res; 1997 Feb 15; 57(4):559-63. PubMed ID: 9044824
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
    Bauer TW, Liu W, Fan F, Camp ER, Yang A, Somcio RJ, Bucana CD, Callahan J, Parry GC, Evans DB, Boyd DD, Mazar AP, Ellis LM.
    Cancer Res; 2005 Sep 01; 65(17):7775-81. PubMed ID: 16140945
    [Abstract] [Full Text] [Related]

  • 5. Amplification of the urokinase gene and the sensitivity of prostate cancer cells to urokinase inhibitors.
    Helenius MA, Savinainen KJ, Bova GS, Visakorpi T.
    BJU Int; 2006 Feb 01; 97(2):404-9. PubMed ID: 16430655
    [Abstract] [Full Text] [Related]

  • 6. Synthesis and preliminary evaluation of amiloride analogs as inhibitors of the urokinase-type plasminogen activator (uPA).
    Matthews H, Ranson M, Tyndall JD, Kelso MJ.
    Bioorg Med Chem Lett; 2011 Nov 15; 21(22):6760-6. PubMed ID: 21978672
    [Abstract] [Full Text] [Related]

  • 7. Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model.
    Frandsen TL, Holst-Hansen C, Nielsen BS, Christensen IJ, Nyengaard JR, Carmeliet P, Brünner N.
    Cancer Res; 2001 Jan 15; 61(2):532-7. PubMed ID: 11212246
    [Abstract] [Full Text] [Related]

  • 8. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
    Merchan JR, Tang J, Hu G, Lin Y, Mutter W, Tong C, Karumanchi SA, Russell SJ, Sukhatme VP.
    J Natl Cancer Inst; 2006 Jun 07; 98(11):756-64. PubMed ID: 16757700
    [Abstract] [Full Text] [Related]

  • 9. Effects of N-(4-hydroxyphenyl) retinamide on urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in prostate adenocarcinoma cell lines.
    Tanabe T.
    Hiroshima J Med Sci; 2000 Mar 07; 49(1):67-72. PubMed ID: 10824459
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion.
    Quemener C, Gabison EE, Naïmi B, Lescaille G, Bougatef F, Podgorniak MP, Labarchède G, Lebbé C, Calvo F, Menashi S, Mourah S.
    Cancer Res; 2007 Jan 01; 67(1):9-15. PubMed ID: 17210677
    [Abstract] [Full Text] [Related]

  • 12. The urokinase inhibitor p-aminobenzamidine inhibits growth of a human prostate tumor in SCID mice.
    Billström A, Hartley-Asp B, Lecander I, Batra S, Astedt B.
    Int J Cancer; 1995 May 16; 61(4):542-7. PubMed ID: 7759160
    [Abstract] [Full Text] [Related]

  • 13. Plasminogen activator and metalloprotease activities of Du-145, PC-3, and 1-LN-PC-3-1A human prostate tumors grown in nude mice: correlation with tumor invasive behavior.
    Wilson MJ, Sinha AA.
    Cell Mol Biol Res; 1993 May 16; 39(8):751-60. PubMed ID: 7951414
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer.
    Li XF, Yan PJ, Shao ZM.
    Oncogene; 2009 Nov 05; 28(44):3937-48. PubMed ID: 19701247
    [Abstract] [Full Text] [Related]

  • 16. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
    Han B, Nakamura M, Zhou G, Ishii A, Nakamura A, Bai Y, Mori I, Kakudo K.
    Int J Oncol; 2006 Apr 05; 28(4):807-14. PubMed ID: 16525628
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428.
    Xing RH, Mazar A, Henkin J, Rabbani SA.
    Cancer Res; 1997 Aug 15; 57(16):3585-93. PubMed ID: 9270032
    [Abstract] [Full Text] [Related]

  • 19. Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1.
    Zhao G, Yuan C, Wind T, Huang Z, Andreasen PA, Huang M.
    J Struct Biol; 2007 Oct 15; 160(1):1-10. PubMed ID: 17692534
    [Abstract] [Full Text] [Related]

  • 20. Wound-induced migration of MDA-MB-435 and SKOV-3 cancer cells is regulated by plasminogen activator inhibitor-1.
    Whitley BR, Church FC.
    Int J Oncol; 2005 Sep 15; 27(3):749-57. PubMed ID: 16077925
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.